Search

Background: Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. This study was conducted to assess if the expression of CAIX in tumour tissue and/or plasma can be a prognostic factor in patients with non-small cell lung cancer (NSCLC).Methods: Tissue microarrays containing 555 NSCLC tissue samples were generated for quantification of CAIX expression. The plasma level of CAIX was determined by ELISA in 209 of these NSCLC patients and in 58 healthy individuals. The CAIX tissue immunostaining and plasma levels were correlated with clinicopathological factors and patient outcome.Results: CAIX tissue overexpression correlated with shorter overall survival (OS) (P=0.05) and disease-specific survival (DSS) of patients (P=0.002). The CAIX plasma level was significantly higher in patients with NSCLC than in healthy individuals (P<0.001). A high level of CAIX in the plasma of patients was associated with shorter OS (P<0.001) and DSS (P<0.001), mostly in early stage I+II NSCLC. Multivariate Cox analyses revealed that high CAIX tissue expression (P=0.002) was a factor of poor prognosis in patients with resectable NSCLC. In addition, a high CAIX plasma level was an independent variable predicting poor OS (P<0.001) in patients with NSCLC.Conclusion: High expression of CAIX in tumour tissue is a predictor of worse survival, and a high CAIX plasma level is an independent prognostic biomarker in patients with NSCLC, in particular in early-stage I+II carcinomas. [ABSTRACT FROM AUTHOR]

Copyright of Oncologie (Tech Science Press) is the property of Tech Science Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Oncologie (Tech Science Press) is the property of Tech Science Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Oncologie (Tech Science Press) is the property of Tech Science Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Abstract: This paper is an overview of the French experience with contact X-ray radiation for rectal cancer. The analysis was mainly carried out on 50 years of experience in Lyon or since 1980 in the Centre Hospitalier Universitaire Lyon Sud. The results obtained in Dijon and Nancy are also reported. In early rectal cancer, contact X-ray radiation can play an important role in three different situations: (1) small T1 less than 2cm: adjuvant contact X-ray radiotherapy after local excision; (2) T2 N0 or large T1: first-line contact X-ray radiotherapy combined with external beam radiotherapy (±chemotherapy) followed by surgery (anterior resection or local excision); (3) early T3 N0 in frail patients: the same approach as for T2 N0 with, in case of clinical complete response, local excision or follow-up. [Copyright &y& Elsevier]

To evaluate the oncological outcome after stereotactic body radiation therapy (SBRT) for oligometastatic (OM) prostate cancer (PC) patients. In this retrospective observational multi-institutional study (Health-data-hub N°F20210402112942), patients with OM (≤ 5) PC underwent SBRT. While patients were enrolled irrespective of PC initial treatment, castration sensitive (CS)/resistant (CR) and synchronous (SM)/metachronous (MM) metastatic disease status were taken into account. Primary endpoint was systemic therapy postponement (STP) after SBRT. Oncological outcome was assessed by post-SBRT biochemical response, local (LR; in SBRT field), metastatic (MR), prostatic (PR) and isolated biochemical (iBR) relapses. PSA kinetic (PSAdt; velocity) and prognostic factors for STP were investigated. Toxicity was reported (CTCAE v5). From 01/07 to 09/19, 169 pts (median age 71.4 y [48.7 – 100.1]) underwent SBRT. At the time of SBRT, 151 pts (89.3%) and 18 pts (10.7%) were MM and SM respectively and 119 pts (70.4%) and 50 pts (29.6%) were CS and CR respectively. Median PSA, PSAdt and velocity were 2.4 ng/ml [0.01 – 277], 5.2 months [0.9 – 45.2] and 2.3 ng/ml/an [0.1 – 25.9] respectively. Median time between initial PC/metastatic disease (TPCMD) and metastatic disease/SBRT were 68.9 months [1.9 – 273.4] and 3.1 months [0.1 – 97.9]. Metastatic anatomic sites were pelvic (PLN) and extra-pelvic lymph nodes (EPLN), bone and brain for 58 pts (34.4%), 15 pts (8.9%), 92 pts (54.4%) and 4 pts (2.4%) respectively. SBRT regimens were 27 Gy/3f (29%), 35 Gy/5f (24.3%), 36 Gy/6f (18.3%) and other (28.4%). With a MFU of 27.5 months [1 – 100.5], median time between SBRT/1st PSA control was 2 months [0.5 – 29]. PSA decreased in 67.4%, was stable in 9.4% and increased in 23.2%. Eighty-eight pts (52.1%) underwent post-SBRT systemic therapy after a median STP of 15.4 months [2.6 – 86.9]. One hundred and thirty events (LR, MR, PR, iBR) were observed in 106 pts (62.7%), among whom 13 (12.3%) relapsed in the irradiated area (local control rate: 92.3%). MR, PR, iBR were observed in 82 pts (77.4%), 33 pts (31.1 %) and 2 pts (1.9 %) respectively. Prognostic factors for STP after SBRT were: hormonal status (CS vs CR: 20.9 vs 10.8 months; p < 0.001), post-SBRT biochemical response ([declined + stable] PSA vs increased PSA: 21 vs 11 months; p = 0.004) and TPCMD (< 42 vs ≥ 42 months; p < 0.001). G≥3 toxicity occurred in 4 pts: 2 pts with G3 post-SBRT fracture (1 surgery), 1 pt with G3 radiation pneumonitis and 1 pt with G4 intracranial hypertension (emergency surgery). SBRT for oligometastatic prostate cancer is an option to postpone systemic therapy, mainly for CS and MM patients with an acceptable toxicity profile. Patient selection criteria remain a crucial goal in order to refine SBRT indications, while the impact of combination with systemic therapy remains under investigation. [ABSTRACT FROM AUTHOR]

Résumé Le traitement de référence des carcinomes épidermoïdes du canal anal localement évolués (stades II et III) est la chimioradiothérapie exclusive. Celle-ci délivre une dose de 45 Gy à raison de cinq fractions de 1,8 Gy par semaine dans un volume pelvien, puis un complément de dose de 14 à 20 Gy dans la tumeur. La chimiothérapie concomitante la plus souvent utilisée comprend une association de 5-fluoro-uracile et de mitomycine-C délivrée lors de la première et cinquième semaine d’irradiation. Une couverture optimale des volumes cibles est parfois difficile à obtenir avec une irradiation conformationnelle (jonctions des faisceaux, combinaison d’électrons et photons parfois complexes dans les aires ganglionnaires). La toxicité cutanéomuqueuse et digestive induite par le traitement peut nécessiter un intervalle libre avant la réalisation du complément d’irradiation. Celui-ci peut avoir un effet délétère sur les résultats s’il est prolongé (plus de 38 jours). Les différentes techniques de radiothérapie conformationnelle avec modulation d’intensité (statique segmentée, dynamique, arcthérapie volumique modulée et tomothérapie hélicoïdale) ont leur intérêt dans cette localisation. Elles permettent d’obtenir une stérilisation tumorale et ganglionnaire avec une baisse des doses intermédiaires et élevées aux organes à risque (intestin grêle, périnée/organes génitaux, vessie, moelle osseuse) entraînant une réduction de la toxicité aiguë de grade 3 ou plus ainsi qu’une meilleure conservation fonctionnelle du sphincter anorectal. Une description de la réalisation de l’arcthérapie volumique modulée est présentée dans cet article. Les avantages et inconvénients de cette technique par rapport aux autres y sont discutés. The standard treatment of locally advanced (stage II and III) squamous cell carcinoma of the anal canal consists of concurrent chemoradiotherapy (two cycles of 5-fluoro-uracil, mitomycin C, on a 28-day cycle), with a dose of 45 Gy in 1.8 Gy per fraction in the prophylactic planning target volume and additional 14 to 20 Gy in the boost planning target volume (5 days per week) with a possibility of 15 days gap period between the two sequences. While conformal irradiation may only yield suboptimal tumor coverage using complex photon/electron field junctions (especially on nodal areas), intensity modulated radiation therapy techniques (segmented static, dynamic, volumetric modulated arc therapy and helical tomotherapy) allow better tumour coverage while sparing organs at risk from intermediate/high doses (small intestine, perineum/genitalia, bladder, pelvic bone, etc.). Such dosimetric advantages result in fewer severe acute toxicities and better potential to avoid a prolonged treatment break that increases risk of local failure. These techniques also allow a reduction in late gastrointestinal and skin toxicities of grade 3 or above, as well as better functional conservation of anorectal sphincter. The technical achievements (simulation, contouring, prescription dose, treatment planning, control quality) of volumetric modulated arctherapy are discussed. [ABSTRACT FROM AUTHOR]